Pharmaceutical Amorphous Nanoparticles

Journal of Pharmaceutical Sciences

Volumn 106, Issue 1, 2017, Pages 39-65

  Jog, Rajan ^a   Burgess, Diane J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

amorphous; bioavailability; calorimetry; dissolution; nanocrystalline; nanoparticles; solid state; solubility; stability; X ray diffraction

Indexed keywords

AMORPHOUS NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; POLYELECTROLYTE; UNCLASSIFIED DRUG; DRUG; DRUG CARRIER;

DISSOLUTION; ELECTROSPINNING; NANOENCAPSULATION; PHYSICAL CHEMISTRY; POROSITY; PRECIPITATION; REVIEW; SONOPRECIPITATION; ANIMAL; CHEMISTRY; CRYSTALLIZATION; DEVICES; ELECTROCHEMICAL ANALYSIS; EQUIPMENT DESIGN; HUMAN; NANOTECHNOLOGY; PHARMACOKINETICS; PROCEDURES; SOLUBILITY; SUPERCRITICAL FLUID CHROMATOGRAPHY; ULTRASOUND;

ANIMALS; CHROMATOGRAPHY, SUPERCRITICAL FLUID; CRYSTALLIZATION; DRUG CARRIERS; ELECTROCHEMICAL TECHNIQUES; EQUIPMENT DESIGN; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; SONICATION;

EID: 85002564019     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.09.014     Document Type: Review

References (198)

1. 1 Lipinski, C., Poor aqueous solubility—an industry wide problem in drug discovery. Am Pharm Rev 5:3 (2002), 82–85.
2. 2 Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 64 (2012), 4–17.
3. 3 Lipinski, C.A., Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:1 (2000), 235–249.
4. 4 Gribbon, P., Andreas, S., High-throughput drug discovery: what can we expect from HTS?. Drug Discov Today 10:1 (2005), 17–22.
5. 5 Hann, M.M., Oprea, T.I., Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 8:3 (2004), 255–263.
6. 6 Yamashita, S., In vitro-in vivo correlations: application to water insoluble drugs. Bull Tech Gattefosse, 1998, 25–32.
7. 7 Caldwell, G.W., Ritchie, D.M., Masucci, J.A., Hageman, W., Yan, Z., The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr Top Med Chem 1:5 (2001), 353–366.
8. 8 Prentis, R.A., Lis, Y., Walker, S.R., Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-985). Br J Clin Pharmacol 25:3 (1988), 387–396.
9. 9 Hartmann, T., Schmitt, J., Rohring, C., Nimptsch, D., Noller, J., Mohr, C., ADME related profiling in 96 and 384 well plate format—a novel and robust HT-assay for the determination of lipophilicity and serum albumin binding. Curr Drug Deliv 3:2 (2006), 181–192.
10. 10 Verma, S., Huey, B.D., Burgess, D.J., Scanning probe microscopy method for nanosuspension stabilizer selection. Langmuir 25:21 (2009), 12481–12487.
11. 11 Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R., Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18:2 (2003), 113–120.
12. 12 Merisko-Liversidge, E.M., Liversidge, G.G., Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 36:1 (2008), 43–48.
13. 13 Thomson, W., On the equilibrium of vapour at a curved surface of liquid. Proc R Soc Edinb 7 (1872), 63–68.
14. 14 Van Eerdenbrugh, B., Vermant, J., Martens, J.A., et al. Solubility increases associated with crystalline drug nanoparticles: methodologies and significance. Mol Pharm 7:5 (2010), 1858–1870.
15. 15 Chiou, W.L., Riegelman, S., Oral absorption of griseofulvin in dogs: increased absorption viasolid dispersion in polyethylene glycol 6000. J Pharm Sci 59:7 (1970), 937–942.
16. 16 Hancock, B.C., Parks, M., What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res 17:4 (2000), 397–404.
17. 17 Leuner, C., Dressman, J., Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:1 (2000), 47–60.
18. 18 Serajuddin, A., Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:10 (1999), 1058–1066.
19. 19 Chen, X., Young, T.J., Sarkari, M., Williams, R.O., Johnston, K.P., Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm 242:1 (2002), 3–14.
20. 20 Lindfors, L., Skantze, P., Skantze, U., Rasmusson, M., Zackrisson, A., Olsson, U., Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 22:3 (2006), 906–910.
21. 21 Zhang, J.Y., Shen, Z.G., Zhong, J., et al. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm 323:1 (2006), 153–160.
22. 22 Wang, J.X., Zhang, Q.X., Zhou, Y., Shao, L., Chen, J.F., Microfluidic synthesis of amorphous cefuroxime axetil nanoparticles with size-dependent and enhanced dissolution rate. Chem Eng J 162:2 (2010), 844–851.
23. 23 Zhu, W.Z., Wang, J.X., Shao, L., Zhang, H.X., Zhang, Q.X., Chen, J.F., Liquid antisolvent preparation of amorphous cefuroxime axetil nanoparticles in a tube-in-tube microchannel reactor. Int J Pharm 395:1 (2010), 260–265.
24. 24 Waard de, H., Frijlink, H.W., Hinrichs, W.L.J., Bottom-up preparation techniques for nanocrystals of lipophilic drugs. Pharm Res 28:5 (2011), 1220–1223.
25. 25 Pace, S.N., Pace, G.W., Parikh, I., Mishra, A.K., Novel injectable formulations of insoluble drugs. Pharm Technol 23:3 (1999), 116–134.
26. 26 Young, T.J., Mawson, S., Johnston, K.P., Henriksen, I.B., Pace, G.W., Mishra, A.K., Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol Prog 16:3 (2000), 402–407.
27. 27 Heng, D., Lee, S.H., Ng, W.K., Tan, R.B.H., The nano spray dryer B-90. Expert Opin Drug Deliv 8:7 (2011), 965–972.
28. 28 Xie, J., Lim, L.K., Phua, Y., Hua, J., Wang, C.-H., Electrohydrodynamic atomization for biodegradable polymeric particle production. J Colloid Interf Sci 302:1 (2006), 103–112.
29. 29 Zhang, S., Kawakami, K., Yamamoto, M., et al. Coaxial electrospray formulations for improving oral absorption of a poorly water-soluble drug. Mol Pharm 8:3 (2011), 807–813.
30. 30 Ravichandran, R., Nanoparticles in drug delivery: potential green nanobiomedicine applications. Int J Nanotechnol Biomed 1:2 (2009), B108–B130.
31. 31 Nekkanti, V., Pillai, R., Vabalaboina, V., Drug Nanoparticles—An Overview. 2012, INTECH Open Access Publisher, Rijeka, Croatia.
32. 32 Patravale, V.B., Kulkarni, R.M., Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 56:7 (2004), 827–840.
33. 33 Junghanns, J.U.A.H., Muller, R.H., Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed, 3(3), 2008, 295.
34. 34 Kumar, S., Burgess, D.J., Nanosuspensions. Wright, J.C., Burgess, D.J., (eds.) Long Acting Injections and Implants, 2012, Springer, New York, NY, 239–261.
35. 35 Loh, Z.H., Samanta, A.K., Heng, P.W.S., Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J Pharm Sci 10:4 (2015), 255–274.
36. 36 Juhnke, M., Weichert, R., Nanoparticles of soft materials by high-energy milling at low temperatures. 7th World Congress of Chemical Engineering, 2005, Germany.
37. 37 Xie, Y., Cho, J., Kim, S., Park, K., Nanotechnology in drug delivery. Xie, Y., (eds.) The Nanobiotechnology Handbook, 2013, CRC Press, Boca Raton, FL, 519–534.
38. 38 Morales, J.O., Watts, A.B., McConville, J.T., Mechanical particle-size reduction techniques. Williams, R.O., Watts, A.B., Miller, D.A., (eds.) Formulating Poorly Water Soluble Drugs, 2012, Springer, London, 133–170.
39. 39 Kumar, A., Chen, F., Mozhi, A., et al. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale 5:18 (2013), 8307–8325.
40. 40 Salazar, J., Muller, R.H., Moschwitzer, J.P., Combinative particle size reduction technologies for the production of drug nanocrystals. J Pharm 2014:2014 (2014), 1–15.
41. 41 Gruverman, I.J., Thumm, J.R., Production of nanostructures under ultraturbulent collision reaction conditions—application to catalysts, superconductors, CMP abrasives, ceramics, and other nanoparticles. MRS Proc, P9, 2003, 7.
42. 42 Panagiotou, T., Mesite, S., Fisher, R., Gruverman, I., Production of stable drug nanospensions using microfluidics reaction technology. Proceedings of the NSTI Nanotechnology Conference and Trade Show. Santa Clara, CA, 2007, 246–249.
43. 43 Liversidge, G.G., Cundy, K.C., Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125:1 (1995), 91–97.
44. 44 Pilcer, G., Sebti, T., Amighi, K., Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 23:5 (2006), 931–940.
45. 45 Huang, Y., Dai, W.G., Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B 4:1 (2014), 18–25.
46. 46 Vaka, S.R.K., Bommana, M.M., Desai, D., Djordjevic, J., Phuapradit, W., Shah, N., Excipients for amorphous solid dispersions. Shah, N., Sandhu, H., Choi, D.S., Choksi, H., Malick, W., (eds.) Amorphous Solid Dispersions, 2014, Springer, New York, NY, 123–161.
47. 47 Baghel, S., Cathcart, H., O'Reilly, N.J., Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci 105:9 (2016), 2527–2544.
48. 48 Gulsun, T., Gursoy, R.N., Levent, O., Nanocrystal technology for oral delivery of poorly water-soluble drugs. FARAD J Pharm Sci 34 (2009), 55–65.
49. 49 Moschwitzer, J.P., Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 453:1 (2013), 142–156.
50. 50 Junyaprasert, V.B., Morakul, B., Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci 10:1 (2015), 13–23.
51. 51 Lee, J., Drug nano- and microparticles processed into solid dosage forms: physical properties. J Pharm Sci 92:10 (2003), 2057–2068.
52. 52 Van Eerdenbrugh, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., Van den Mooter, G., Drying of crystalline drug nanosuspensions—the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci 35:1 (2008), 127–135.
53. 53 Solid solutions and dispersions. 3, 2012, Particle Sciences, Drug Development Services, Bethlehem, PA.
54. 54 Amstad, E., Gopinadhan, M., Holtze, C., et al. Production of amorphous nanoparticles by supersonic spray-drying with a microfluidic nebulator. Science 349:6251 (2015), 956–960.
55. 55 Rainer, H.M., Junghanns, A.H., Drug nanocrsytals/nanosuspensions for the delivery of poorly soluble drugs. Torchilin, V.P., (eds.) Nanoparticulates as Drug Carriers, 2006, Imperial College Press, London.
56. 56 Bellantone, R.A., Fundamentals of amorphous systems: thermodynamic aspects. Shah, N., Sandhu, H., Choi, D.S., Choksi, H., Malick, W., (eds.) Amorphous Solid Dispersions, 2014, Springer, New York, NY, 3–34.
57. 57 Suslick, K.S., Sonochemistry. Science 247 (1990), 1439–1445.
58. 58 Thunemann, A.F., Polyelectrolyte-surfactant complexes (synthesis, structure and materials aspects). Prog Polym Sci 27:8 (2002), 1473–1572.
59. 59 Desgouilles, S.P., Vauthier, C., Bazile, D., et al. The design of nanoparticles obtained by solvent evaporation: a comprehensive study. Langmuir 19:22 (2003), 9504–9510.
60. 60 Dillen, K., Vandervoort, J., Van den Mooter, G., Verheyden, L., Ludwig, A., Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm 275:1 (2004), 171–187.
61. 61 Ramos, L., Schonhoff, M., Luan, Y., Mohwald, H., Brezesinski, G., Electrostatic interactions between polyelectrolyte and amphiphiles in two-and three-dimensional systems. Colloids Surf A Physicochem Eng Aspects 303:1 (2007), 79–88.
62. 62 Taylor, D.J.F., Thomas, R.K., Penfold, J., Polymer/surfactant interactions at the air/water interface. Adv Colloid Interface Sci 132:2 (2007), 69–110.
63. 63 Dhumal, R.S., Biradar, S.V., Yamamura, S., Paradkar, A.R., York, P., Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur J Pharm Biopharm 70:1 (2008), 109–115.
64. 64 Matteucci, M.E., Paguio, J.C., Miller, M.A., Williams Iii, R.O., Johnston, K.P., Flocculated amorphous nanoparticles for highly supersaturated solutions. Pharm Res 25:11 (2008), 2477–2487.
65. 65 Chi, N.T., Triet, N.M., Chien, D.M., Preparation of drug nanoparticles by emulsion evaporation method. J Phys Conf Ser, 187, 2009, 012047.
66. 66 Zhu, Z., Margulis-Goshen, K., Magdassi, S., Talmon, Y., Macosko, C.W., Polyelectrolyte stabilized drug nanoparticles via flash nanoprecipitation: a model study with beta-carotene. J Pharm Sci 99:10 (2010), 4295–4306.
67. 67 Zeiger, B.W., Suslick, K.S., Sonofragmentation of molecular crystals. J Am Chem Soc 133:37 (2011), 14530–14533.
68. 68 Cheow, W.S., Hadinoto, K., Self-assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility. J Colloid Interface Sci 367:1 (2012), 518–526.
69. 69 Guo, P., Hsu, T.M., Zhao, Y., Martin, C.R., Zare, R.N., Preparing amorphous hydrophobic drug nanoparticles by nanoporous membrane extrusion. Nanomedicine 8:3 (2013), 333–341.
70. 70 Lonare, A.A., Patel, S.R., Antisolvent crystallization of poorly water soluble drugs. Int J Chem Eng Appl, 4(5), 2013, 337.
71. 71 Cheow, W.S., Kiew, T.Y., Yang, Y., Hadinoto, K., Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles. Mol Pharm 11:5 (2014), 1611–1620.
72. 72 Homayouni, A., Sadeghi, F., Varshosaz, J., Garekani, H.A., Nokhodchi, A., Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques. Colloids Surf B Biointerfaces 122 (2014), 591–600.
73. 73 Zu, Y., Sun, W., Zhao, X., et al. Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation. Eur J Pharm Sci 53 (2014), 109–117.
74. 74 Wijesena, R.N., Tissera, N., Kannangara, Y.Y., Lin, Y., Amaratunga, G.A.J., de Silva, K.M.N., A method for top down preparation of chitosan nanoparticles and nanofibers. Carbohydr Polym 117 (2015), 731–738.
75. 75 Dizaj, S.M., Vazifehasl, Z., Salatin, S., Adibkia, K., Javadzadeh, Y., Nanosizing of drugs: effect on dissolution rate. Res Pharm Sci, 10(2), 2015, 95.
76. 76 Montes, A., Pereyra, C., de la Ossa, E.J.M., Gordillo, M.D., Particles Formation Using Supercritical Fluids. 2011, INTECH Open Access Publisher, Rijeka, Croatia.
77. 77 Sheth, P., Sandhu, H., Amorphous solid dispersion using supercritical fluid technology. Amorphous Solid Dispersions, 2014, Springer, New York, 579–591.
78. 2. Austria: Natex, 2005.
79. 79 Yoshida, V.M.H., Balcao, V.M., Vila, M.M.D.C., et al. Supercritical fluid and pharmaceutical applications. Part I: process classification. Afr J Pharm Pharmacol 10:9 (2016), 132–144.
80. 80 Rowe, J.M., Johnston, K.P., Precipitation technologies for nanoparticle production. Williams, R.O. III, Watts, A.B., Miller, D.A., (eds.) Formulating Poorly Water Soluble Drugs, 2012, Springer, New York, NY, 501–568.
81. 81 Qian, K.K., Bogner, R.H., Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. J Pharm Sci 101:2 (2012), 444–463.
82. 82 Liberman, A., Mendez, N., Trogler, W.C., Kummel, A.C., Synthesis and surface functionalization of silica nanoparticles for nanomedicine. Surf Sci Rep 69:2 (2014), 132–158.
83. 83 Petushkov, A., Ndiege, N., Salem, A.K., Larsen, S.C., Toxicity of silica nanomaterials: zeolites, mesoporous silica, and amorphous silica nanoparticles. Adv Mol Toxicol 4 (2010), 223–266.
84. 84 Bharti, C., Nagaich, U., Pal, A.K., Gulati, N., Mesoporous silica nanoparticles in target drug delivery system: a review. Int J Pharm Investig, 5(3), 2015, 124.
85. 85 Zhang, H., Dunphy, D.R., Jiang, X., et al. Processing pathway dependence of amorphous silica nanoparticle toxicity: colloidal vs pyrolytic. J Am Chem Soc 134:38 (2012), 15790–15804.
86. 86 Tarn, D., Ashley, C.E., Xue, M., Carnes, E.C., Zink, J.I., Brinker, C.J., Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc Chem Res 46:3 (2013), 792–801.
87. 87 Yu, D.G., Zhu, L.M., White, K., Branford-White, C., Electrospun nanofiber-based drug delivery systems. Health, 1(02), 2009, 67.
88. 88 Ignatious, F., Sun, L., Lee, C.P., Baldoni, J., Electrospun nanofibers in oral drug delivery. Pharm Res 27:4 (2010), 576–588.
89. 89 Verreck, G., Chun, I., Peeters, J., Rosenblatt, J., Brewster, M.E., Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm Res 20:5 (2003), 810–817.
90. 90 Thassu, D., Deleers, M., Pathak, Y.V., Nanoparticulate Drug Delivery Systems. 2007, CRC Press, Boca Raton, FL.
91. 91 Haghi, A.K., Thomas, S., Pourhashemi, A., Hamrang, A., Klodzinska, E., Nanomaterials and Nanotechnology for Composites: Design, Simulation and Applications. 2015, CRC Press, Boca Raton, FL.
92. 92 Cheow, W.S., Kiew, T.Y., Hadinoto, K., Amorphous nanodrugs prepared by complexation with polysaccharides: carrageenan versus dextran sulfate. Carbohydr Polym 117 (2015), 549–558.
93. 93 Jog, R., Kumar, S., Shen, J., et al. Formulation design and evaluation of amorphous ABT-102 nanoparticles. Int J Pharm 498:1 (2016), 153–169.
94. 94 Kumar, S., Shen, J., Burgess, D.J., Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole. J Control Release 192 (2014), 95–102.
95. 95 Yang, W., Johnston, K.P., Williams, R.O., Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm 75:1 (2010), 33–41.
96. 96 Matteucci, M.E., Brettmann, B.K., Rogers, T.L., Elder, E.J., Williams Iii, R.O., Johnston, K.P., Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol Pharm 4:5 (2007), 782–793.
97. 97 Kho, K., Hadinoto, K., Dry powder inhaler delivery of amorphous drug nanoparticles: effects of the lactose carrier particle shape and size. Powder Technol 233 (2013), 303–311.
98. 98 Smitha, K.T., Anitha, A., Furuike, T., Tamura, H., Nair, S.V., Jayakumar, R., In vitro evaluation of paclitaxel loaded amorphous chitin nanoparticles for colon cancer drug delivery. Colloids Surf B Biointerfaces 104 (2013), 245–253.
99. 99 Liu, Y., Sun, C., Hao, Y., Jiang, T., Zheng, L., Wang, S., Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. J Pharm Pharm Sci 13:4 (2010), 589–606.
100. 100 Papadimitriou, S., Bikiaris, D., Novel self-assembled core-shell nanoparticles based on crystalline amorphous moieties of aliphatic copolyesters for efficient controlled drug release. J Control Release 138:2 (2009), 177–184.
101. 101 Thadkala, K., Nanam, P.K., Rambabu, B., Sailu, C., Aukunuru, J., Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability. Int J Pharm Investig, 4(3), 2014, 131.
102. 102 Kim, M.S., Jin, S.J., Kim, J.-S., et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 69:2 (2008), 454–465.
103. 103 Yu, L., Li, C., Le, Y., Chen, J.F., Zou, H., Stabilized amorphous glibenclamide nanoparticles by high-gravity technique. Mater Chem Phys 130:1 (2011), 361–366.
104. 104 Tran, T.T.D., Tran, P.H.L., Nguyen, M.N.U., et al. Amorphous isradipine nanosuspension by the sonoprecipitation method. Int J Pharm 474:1 (2014), 146–150.
105. 105 Romero, G.B., Arntjen, A., Keck, C.M., Muller, R.H., Amorphous cyclosporin A nanoparticles for enhanced dermal bioavailability. Int J Pharm 498:1 (2016), 217–224.
106. 106 Baig, M.S., Ahad, A., Aslam, M., Imam, S.S., Aqil, M., Ali, A., Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: optimization, in vitro release, ocular tolerance, and antibacterial activity. Int J Biol Macromol 85 (2016), 258–270.
107. 107 Parikh, T., Sandhu, H.K., Talele, T.T., Serajuddin, A.T.M., Characterization of solid dispersion of itraconazole prepared by solubilization in concentrated aqueous solutions of weak organic acids and drying. Pharm Res 33:6 (2016), 1456–1471.
108. 108 Nguyen, M.H., Tran, T.-T., Hadinoto, K., Controlling the burst release of amorphous drug-polysaccharide nanoparticle complex via crosslinking of the polysaccharide chains. Eur J Pharm Biopharm 104 (2016), 156–163.
109. 109 Li, J., Wang, H., Yang, B., et al. Control-release microcapsule of famotidine loaded biomimetic synthesized mesoporous silica nanoparticles: controlled release effect and enhanced stomach adhesion in vitro. Mater Sci Eng C Mater Biol Appl 58 (2016), 273–277.
110. 110 Dalmolin, L.F., Khalil, N.M., Mainardes, R.M., Delivery of vanillin by poly (lactic-acid) nanoparticles: development, characterization and in vitro evaluation of antioxidant activity. Mater Sci Eng C Mater Biol Appl 62 (2016), 1–8.
111. 111 Ngwuluka, N.C., Kotak, D.J., Devarajan, P.V., Design and characterization of metformin-loaded solid lipid nanoparticles for colon cancer. AAPS Pharm Sci Tech 17 (2016), 1–11.
112. 112 Huang, P.H., Hu, S.C.S., Lee, C.W., Yeh, A.C., Tseng, C.H., Yen, F.L., Design of acid-responsive polymeric nanoparticles for 7, 3', 4'-trihydroxyisoflavone topical administration. Int J Nanomed, 11, 2016, 1615.
113. 113 Chonkar, A.D., Rao, J.V., Managuli, R.S., et al. Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation. Eur J Pharm Biopharm 103 (2016), 179–191.
114. 114 Suto, B., Berko, S., Kozma, G., et al. Development of ibuprofen-loaded nanostructured lipid carrier-based gels: characterization and investigation of in vitro and in vivo penetration through the skin. Int J Nanomed, 11, 2016, 1201.
115. 115 Burapapadh, K., Takeuchi, H., Sriamornsak, P., Development of pectin nanoparticles through mechanical homogenization for dissolution enhancement of itraconazole. Asian J Pharm Sci 11:3 (2016), 365–375.
116. 116 Omwoyo, W.N., Melariri, P., Gathirwa, J.W., et al. Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles. Nanomedicine 12:3 (2016), 801–809.
117. 117 Zhu, D., Tao, W., Zhang, H., et al. Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Acta Biomater 30 (2016), 144–154.
118. 118 Shi, A., Li, D., Liu, H., Adhikari, B., Wang, Q., Effect of drying and loading methods on the release behavior of ciprofloxacin from starch nanoparticles. Int J Biol Macromol 87 (2016), 55–61.
119. 119 Parhizkar, M., Reardon, P.J.T., Knowles, J.C., et al. Electrohydrodynamic encapsulation of cisplatin in poly (lactic-co-glycolic acid) nanoparticles for controlled drug delivery. Nanomedicine 12:7 (2016), 1919–1929.
120. 120 Ghanbarzadeh, S., Hariri, R., Kouhsoltani, M., Shokri, J., Javadzadeh, Y., Hamishehkar, H., Enhanced stability and dermal delivery of hydroquinone using solid lipid nanoparticles. Colloids Surf B Biointerfaces 136 (2015), 1004–1010.
121. 121 Akl, M.A., Kartal-Hodzic, A., Oksanen, T., et al. Factorial design formulation optimization and in vitro characterization of curcumin-loaded PLGA nanoparticles for colon delivery. J Drug Deliv Sci Technol 32 (2016), 10–20.
122. 122 Gajra, B., Patel, R.R., Dalwadi, C., Formulation, optimization and characterization of cationic polymeric nanoparticles of mast cell stabilizing agent using the Box-Behnken experimental design. Drug Dev Ind Pharm 42:5 (2016), 747–757.
123. 123 Yang, Y.C., Cai, J., Yin, J., Zhang, J., Wang, K.-L., Zhang, Z.T., Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers. Carbohydr Polym 136 (2016), 782–790.
124. 124 Maulvi, F.A., Lakdawala, D.H., Shaikh, A.A., et al. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery. J Control Release 226 (2016), 47–56.
125. 125 Bhattacharya, P., Mondal, S., Basak, S., Das, P., Saha, A., Bera, T., In vitro susceptibilities of wild and drug resistant Leishmania donovani amastigotes to piperolactam A loaded hydroxypropyl-beta-cyclodextrin nanoparticles. Acta Trop 158 (2016), 97–106.
126. 126 Mostafa, A.A., Zaazou, M.H., Chow, L.C., et al. Injectable nanoamorphous calcium phosphate based in situ gel systems for the treatment of periapical lesions. Biomed Mater, 10(6), 2015, 065006.
127. 127 Geetha, P., Sivaram, A.J., Jayakumar, R., Mohan, C.G., Integration of in silico modeling, prediction by binding energy and experimental approach to study the amorphous chitin nanocarriers for cancer drug delivery. Carbohydr Polym 142 (2016), 240–249.
128. 128 Abd-Elrahman, A.A., El Nabarawi, M.A., Hassan, D.H., Taha, A.A., Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization. Drug Deliv 23 (2016), 1–29.
129. 129 Tadros, M.I., Al-mahallawi, A.M., Long-circulating lipoprotein-mimic nanoparticles for smart intravenous delivery of a practically-insoluble antineoplastic drug: development, preliminary safety evaluations and preclinical pharmacokinetic studies. Int J Pharm 493:1 (2015), 439–450.
130. 130 Harmon, P., Galipeau, K., Xu, W., Brown, C., Wuelfing, W.P., Mechanism of dissolution-induced nanoparticle formation from a copovidone-based amorphous solid dispersion. Mol Pharm 13:5 (2016), 1467–1481.
131. 131 Jafari, S., Maleki-Dizaji, N., Barar, J., Barzegar-Jalali, M., Rameshrad, M., Adibkia, K., Methylprednisolone acetate-loaded hydroxyapatite nanoparticles as a potential drug delivery system for treatment of rheumatoid arthritis: in vitro and in vivo evaluations. Eur J Pharm Sci 91 (2016), 225–235.
132. 132 Maged, A., Mahmoud, A.A., Ghorab, M.M., Nano-spray drying technique as a novel approach to formulate stable econazole nitrate nanosuspension formulations for ocular use. Mol Pharm 13 (2016), 2951–2965.
133. 133 Ji, P., Yu, T., Liu, Y., et al. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. Drug Des Dev Ther 10 (2016), 911–925.
134. 134 Krull, S.M., Susarla, R., Afolabi, A., et al. Polymer strip films as a robust, surfactant-free platform for delivery of BCS Class II drug nanoparticles. Int J Pharm 489:1-2 (2015), 45–57.
135. 135 Badran, M.M., Harisa, G.I., AlQahtani, S.A., Alanazi, F.K., Zoheir, K.M.A., Pravastatin-loaded chitosan nanoparticles: formulation, characterization and cytotoxicity studies. J Drug Deliv Sci Technol 32 (2016), 1–9.
136. 136 Najafi, S.H.M., Baghaie, M., Ashori, A., Preparation and characterization of acetylated starch nanoparticles as drug carrier: ciprofloxacin as a model. Int J Biol Macromol 87 (2016), 48–54.
137. 137 Facchi, S.P., Scariot, D.B., Bueno, P.V.A., et al. Preparation and cytotoxicity of N-modified chitosan nanoparticles applied in curcumin delivery. Int J Biol Macromol 87 (2016), 237–245.
138. 138 Zhang, P., Liu, X., Hu, W., Bai, Y., Zhang, L., Preparation and evaluation of naringenin-loaded sulfobutylether-beta-cyclodextrin/chitosan nanoparticles for ocular drug delivery. Carbohydr Polym 149 (2016), 224–230.
139. 139 Su, Y.R., Yu, S.H., Chao, A.C., et al. Preparation and properties of pH-responsive, self-assembled colloidal nanoparticles from guanidine-containing polypeptide and chitosan for antibiotic delivery. Colloids Surfaces A Physicochem Eng Aspects 494 (2016), 9–20.
140. 140 Zhang, Z.B., Xie, M.L., Kuang, Y.Y., et al. Preparation of amorphous drug nanoparticles by high-gravity reactive precipitation technique. Chem Eng Process Process Intensif 104 (2016), 253–261.
141. 141 Lingling, G., Yuan, Z., Weigen, L., Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles. Drug Dev Ind Pharm 42:8 (2016), 1–9.
142. 142 Mazuryk, J., Deptula, T., Polchi, A., et al. Rapamycin-loaded solid lipid nanoparticles: morphology and impact of the drug loading on the phase transition between lipid polymorphs. Colloids Surfaces A Physicochem Eng Aspects 502 (2016), 54–65.
143. 143 Fong, S.Y.K., Ibisogly, A., Bauer-Brandl, A., Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: spray drying versus freeze-drying. Int J Pharm 496:2 (2015), 382–391.
144. 144 Siafaka, P., Betsiou, M., Tsolou, A., et al. Synthesis of folate-pegylated polyester nanoparticles encapsulating ixabepilone for targeting folate receptor overexpressing breast cancer cells. J Mater Sci Mater Med 26:12 (2015), 1–14.
145. 145 Ayadi, F., Bayer, I.S., Marras, S., Athanassiou, A., Synthesis of water dispersed nanoparticles from different polysaccharides and their application in drug release. Carbohydr Polym 136 (2016), 282–291.
146. 146 El-Naggar, M.E., El-Rafie, M.H., El-Sheikh, M.A., El-Feky, G.S., Hebeish, A., Synthesis, characterization, release kinetics and toxicity profile of drug-loaded starch nanoparticles. Int J Biol Macromol 81 (2015), 718–729.
147. 147 Meng, D.L., Shang, L., Feng, X.H., Huang, X.F., Che, X., Xanthoceraside hollow gold nanoparticles, green pharmaceutics preparation for poorly water-soluble natural anti-AD medicine. Int J Pharm 506:1 (2016), 184–190.
148. 148 Karavas, E., Georgarakis, E., Bikiaris, D., Felodipine nanodispersions as active core for predictable pulsatile chronotherapeutics using PVP/HPMC blends as coating layer. Int J Pharm 313:1 (2006), 189–197.
149. 149 Varshosaz, J., Hassanzadeh, F., Mahmoudzadeh, M., Sadeghi, A., Preparation of cefuroxime axetil nanoparticles by rapid expansion of supercritical fluid technology. Powder Technol 189:1 (2009), 97–102.
150. 150 Thakur, R., Gupta, R.B., Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process. Int J Pharm 308:1 (2006), 190–199.
151. 151 Thakur, R., Gupta, R.B., Rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process: formation of griseofulvin nanoparticles. Ind Eng Chem Res 44:19 (2005), 7380–7387.
152. 152 Gadermann, M., Kular, S., Al-Marzouqi, A.H., Signorell, R., Formation of naproxen-polylactic acid nanoparticles from supercritical solutions and their characterization in the aerosol phase. Phys Chem Chem Phys 11:36 (2009), 7861–7868.
153. 153 Tandya, A., Dehghani, F., Foster, N.R., Micronization of cyclosporine using dense gas techniques. J Supercrit Fluids 37:3 (2006), 272–278.
154. 154 Ha, E.S., Kim, J.S., Baek, I.H., Hwang, S.J., Kim, M.S., Enhancement of dissolution and bioavailability of ezetimibe by amorphous solid dispersion nanoparticles fabricated using supercritical antisolvent process. J Pharm Investigation 45:7 (2015), 641–649.
155. 155 Cardoso, M.A.T., Monteiro, G.A., Cardoso, J.P., et al. Supercritical antisolvent micronization of minocycline hydrochloride. J Supercrit Fluids 44:2 (2008), 238–244.
156. 156 Adami, R., Reverchon, E., Jarvenpa, E., Huopalahti, R., Supercritical antisolvent micronization of nalmefene HCl on laboratory and pilot scale. Powder Technol 182:1 (2008), 105–112.
157. 2. J Supercrit Fluids 75 (2013), 21–29.
158. 158 Kalogiannis, C.G., Pavlidou, E., Panayiotou, C.G., Production of amoxicillin microparticles by supercritical antisolvent precipitation. Ind Eng Chem Res 44:24 (2005), 9339–9346.
159. 159 Reverchon, E., Della Porta, G., Falivene, M.G., Process parameters and morphology in amoxicillin micro and submicro particles generation by supercritical antisolvent precipitation. J Supercrit Fluids 17:3 (2000), 239–248.
160. 160 Reverchon, E., De Marco, I., Caputo, G., Della Porta, G., Pilot scale micronization of amoxicillin by supercritical antisolvent precipitation. J Supercrit Fluids 26:1 (2003), 1–7.
161. 161 Tenorio, A., Gordillo, M.D., Pereyra, C., de la Ossa, E.J.M., Controlled submicro particle formation of ampicillin by supercritical antisolvent precipitation. J Supercrit Fluids 40:2 (2007), 308–316.
162. 162 Thakur, R., Gupta, R.B., Production of hydrocortisone micro-and nano-particles using supercritical anti-solvent with enhanced mass transfer. Chem Eng Commun 193:3 (2006), 293–305.
163. 163 Reverchon, E., De Marco, I., Della Porta, G., Rifampicin microparticles production by supercritical antisolvent precipitation. Int J Pharm 243:1 (2002), 83–91.
164. 164 Zhao, X., Zu, Y., Jiang, R., et al. Preparation and physicochemical properties of 10-hydroxycamptothecin (HCPT) nanoparticles by supercritical antisolvent (SAS) process. Int J Mol Sci 12:4 (2011), 2678–2691.
165. 165 Kim, J.S., Kim, M.S., Park, H.J., Jin, S.J., Lee, S., Hwang, S.J., Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm 359:1 (2008), 211–219.
166. 166 Thiering, R., Dehghani, F., Dillow, A., Foster, N.R., The influence of operating conditions on the dense gas precipitation of model proteins. J Chem Technol Biotechnol 75:1 (2000), 29–41.
167. 167 Thiering, R., Dehghani, F., Dillow, A., Foster, N.R., Solvent effects on the controlled dense gas precipitation of model proteins. J Chem Technol Biotechnol 75:1 (2000), 42–53.
168. 168 Muhrer, G., Mazzotti, M., Precipitation of lysozyme nanoparticles from dimethyl sulfoxide using carbon dioxide as antisolvent. Biotechnol Prog 19:2 (2003), 549–556.
169. 169 Kuang, Y.Y., Zhang, Z.B., Xie, M.L., Wang, J.X., Le, Y., Chen, J.F., Large-scale preparation of amorphous cefixime nanoparticles by antisolvent precipitation in a high-gravity rotating packed bed. Ind Eng Chem Res 54:33 (2015), 8157–8165.
170. 170 Mohseni, M., Gilani, K., Mortazavi, S.A., Preparation and characterization of rifampin loaded mesoporous silica nanoparticles as a potential system for pulmonary drug delivery. Iran J Pharm Res 14:1 (2015), 27–34.
171. 171 Vadia, N., Rajput, S., Study on formulation variables of methotrexate loaded mesoporous MCM-41 nanoparticles for dissolution enhancement. Eur J Pharm Sci 45:1 (2012), 8–18.
172. 172 Thomas, M.J.K., Slipper, I., Walunj, A., et al. Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles. Int J Pharm 387:1 (2010), 272–277.
173. 173 Zhang, Y., Zhi, Z., Jiang, T., Zhang, J., Wang, Z., Wang, S., Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release 145:3 (2010), 257–263.
174. 174 Wani, A., Muthuswamy, E., Savithra, G.H.L., Mao, G., Brock, S., Oupicky, D., Surface functionalization of mesoporous silica nanoparticles controls loading and release behavior of mitoxantrone. Pharm Res 29:9 (2012), 2407–2418.
175. 175 Qian, W., Yu, D.G., Li, Y., Liao, Y.Z., Wang, X., Wang, L., Dual drug release electrospun core-shell nanofibers with tunable dose in the second phase. Int J Mol Sci 15:1 (2014), 774–786.
176. 176 Natu, M.V., de Sousa, H.C., Gil, M.H., Effects of drug solubility, state and loading on controlled release in bicomponent electrospun fibers. Int J Pharm 397:1 (2010), 50–58.
177. 177 Tungprapa, S., Jangchud, I., Supaphol, P., Release characteristics of four model drugs from drug-loaded electrospun cellulose acetate fiber mats. Polymer 48:17 (2007), 5030–5041.
178. 178 Verreck, G., Chun, I., Rosenblatt, J., et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J Control Release 92:3 (2003), 349–360.
179. 179 Taepaiboon, P., Rungsardthong, U., Supaphol, P., Drug-loaded electrospun mats of poly (vinyl alcohol) fibres and their release characteristics of four model drugs. Nanotechnology, 17(9), 2006, 2317.
180. 180 Yu, D.G., Williams, G.R., Yang, J.H., Wang, X., Qian, W., Li, Y., Chitosan nanoparticles self-assembled from electrospun composite nanofibers. J Textile Sci Eng 2012 (2012), 1–5.
181. 181 Xie, J., Wang, C.H., Electrospun micro-and nanofibers for sustained delivery of paclitaxel to treat C6 glioma in vitro. Pharm Res 23:8 (2006), 1817–1826.
182. 182 Yu, D.G., Branford-White, C., Shen, X.X., Zhang, X.F., Zhu, L.M., Solid dispersions of ketoprofen in drug-loaded electrospun nanofibers. J Dispers Sci Tech 31:7 (2010), 902–908.
183. 183 Li, X., Kanjwal, M.A., Lin, L., Chronakis, I.S., Electrospun polyvinyl-alcohol nanofibers as oral fast-dissolving delivery system of caffeine and riboflavin. Colloids Surf B Biointerfaces 103 (2013), 182–188.
184. 184 Illangakoon, U.E., Gill, H., Shearman, G.C., et al. Fast dissolving paracetamol/caffeine nanofibers prepared by electrospinning. Int J Pharm 477:1 (2014), 369–379.
185. 185 Nagy, Z.K., Balogh, A., Demuth, B., et al. High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole. Int J Pharm 480:1 (2015), 137–142.
186. 186 Kim, K., Luu, Y.K., Chang, C., et al. Incorporation and controlled release of a hydrophilic antibiotic using poly (lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Control Release 98:1 (2004), 47–56.
187. 187 Yu, D.G., Yang, J.M., Branford-White, C., Lu, P., Zhang, L., Zhu, L.M., Third generation solid dispersions of ferulic acid in electrospun composite nanofibers. Int J Pharm 400:1 (2010), 158–164.
188. 188 Yu, D.G., Gao, L.D., White, K., Branford-White, C., Lu, W.Y., Zhu, L.M., Multicomponent amorphous nanofibers electrospun from hot aqueous solutions of a poorly soluble drug. Pharm Res 27:11 (2010), 2466–2477.
189. 189 Yu, D.G., Branford-White, C., White, K., Li, X.L., Zhu, L.M., Dissolution improvement of electrospun nanofiber-based solid dispersions for acetaminophen. AAPS Pharm Sci Tech 11:2 (2010), 809–817.
190. 190 Li, X.Y., Wang, X., Yu, D.G., et al. Electrospun borneol-PVP nanocomposites. J Nanomater, 2012, 2012, 7.
191. ®-based solid dosage forms of improved dissolution. J Pharm Sci 101:1 (2012), 322–332.
192. 192 Vigh, T., Horvathova, T., Balogh, A., et al. Polymer-free and polyvinylpirrolidone-based electrospun solid dosage forms for drug dissolution enhancement. Eur J Pharm Sci 49:4 (2013), 595–602.
193. 193 Sun, X.Z., Williams, G.R., Hou, X.X., Zhu, L.M., Electrospun curcumin-loaded fibers with potential biomedical applications. Carbohydr Polym 94:1 (2013), 147–153.
194. 194 Nagy, Z.K., Balogh, A., Dravavolgyi, G., et al. Solvent-free melt electrospinning for preparation of fast dissolving drug delivery system and comparison with solvent-based electrospun and melt extruded systems. J Pharm Sci 102:2 (2013), 508–517.
195. 195 Yu, D.G., Shen, X.X., Branford-White, C., White, K., Zhu, L.M., Bligh, S.W.A., Oral fast-dissolving drug delivery membranes prepared from electrospun polyvinylpyrrolidone ultrafine fibers. Nanotechnology, 20(5), 2009, 055104.
196. 196 Yu, D.G., Zhang, X.F., Shen, X.X., Brandford-White, C., Zhu, L.M., Ultrafine ibuprofen-loaded polyvinylpyrrolidone fiber mats using electrospinning. Polym Int 58:9 (2009), 1010–1013.
197. ® L 100-55 nanofibers for colon-targeted drug delivery. Int J Pharm 408:1 (2011), 200–207.
198. 198 Karthikeyan, K., Guhathakarta, S., Rajaram, R., Korrapati, P.S., Electrospun zein/eudragit nanofibers based dual drug delivery system for the simultaneous delivery of aceclofenac and pantoprazole. Int J Pharm 438:1 (2012), 117–122.